CEL-SCI (CVM) Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid Arthritis Index Score in a Second Animal Model
5/6/2013 6:51:40 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CEL-SCI Corporation (NYSE MKT: CVM) today announced results from a recently completed efficacy study in a second animal model of rheumatoid arthritis (RA) using the LEAPS technology (LEAPS), which demonstrates that LEAPS has the potential for use as a therapeutic vaccine to treat different types of RA, each of which possesses different disease characteristics. The study was conducted in collaboration with Dr. Tibor Glant’s research team at Rush University Medical Center.
Help employers find you! Check out all the jobs and post your resume.
comments powered by